目的 探討香砂養(yǎng)胃丸聯(lián)合替普瑞酮膠囊治療慢性萎縮性胃炎的臨床療效。方法 選取2013年5月-2016年5月中國人民解放軍第二五一醫(yī)院收治的慢性萎縮性胃炎患者110例，隨機(jī)分為對(duì)照組和治療組，每組各55例。對(duì)照組口服替普瑞酮膠囊，50 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服香砂養(yǎng)胃丸，9 g/次，2次/d。兩組患者均治療8周。觀察兩組的臨床療效，比較兩組胃黏膜評(píng)分、生理健康總評(píng)分（PCS）、心理健康總評(píng)分（MCS）和血清炎癥因子水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為74.5%、92.7%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組胃黏膜評(píng)分均顯著降低，而PCS和MCS均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組TNF-α、IL-6和IL-8水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 香砂養(yǎng)胃丸聯(lián)合替普瑞酮膠囊治療慢性萎縮性胃炎具有較好的臨床療效，能改善臨床癥狀，降低炎癥反應(yīng)，提高生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Xiangsha Yangwei Pills combined with Teprenone Capsules in treatment of chronic atrophic gastritis. Methods Patients (110 cases) with chronic atrophic gastritis in the 251 st Hospital of PLA from May 2013 to May 2016 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were po administered with Teprenone Capsules, 50 mg/time, three times daily. Patients in the treatment group were po administered with Xiangsha Yangwei Pills on the basis of the control group, 9 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and gastric mucosal score, PCS, MCS, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.5% and 92.7%, respectively, and there was difference between two groups (P<0.05). After treatment, gastric mucosal scores in two groups were significantly decreased, but PCS and MCS in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, TNF-α, IL-6, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xiangsha Yangwei Pills combined with Teprenone Capsules has clinical curative effect in treatment of chronic atrophic gastritis, can improve clinical symptoms, decrease inflammatory response, and increase quality of life, which has a certain clinical application value.